Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation

Blood. 2018 Feb 15;131(7):818-821. doi: 10.1182/blood-2017-10-811729. Epub 2017 Dec 19.

Authors

Amer M Zeidan^{1

2}, Maximilian Stahl^{1

2}, Xin Hu², Rong Wang^{2

3}, Scott F Huntington^{1

2}, Nikolai A Podoltsev^{1

2}, Steven D Gore^{1

2}, Xiaomei Ma^{2

3}, Amy J Davidoff^{2

4}

Affiliations

¹ Department of Internal Medicine, School of Medicine.
² Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center at Yale University School of Medicine.
³ Department of Chronic Disease Epidemiology, School of Public Health, and.
⁴ Department of Health Policy and Management, School of Public Health, Yale University, New Haven, CT.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Azacitidine / administration & dosage
DNA Methylation / drug effects*
Decitabine / administration & dosage
Female
Humans
Male
Middle Aged
Myelodysplastic Syndromes / drug therapy
Myelodysplastic Syndromes / mortality*
Myelodysplastic Syndromes / pathology
Prognosis
Retrospective Studies
Stem Cell Transplantation
Survival Rate
Survivors / statistics & numerical data*

Substances

Decitabine
Azacitidine

Grants and funding